The absence of benzodiazepine craving in a general practice benzodiazepine discontinuation trial

Addict Behav. 2006 Feb;31(2):211-22. doi: 10.1016/j.addbeh.2005.04.024. Epub 2005 Jun 13.

Abstract

This study aimed to assess benzodiazepine craving longitudinally and to describe its time course by means of the Benzodiazepine Craving Questionnaire (BCQ). Subjects were long-term benzodiazepine users participating in a two-part treatment intervention aimed to reduce long-term benzodiazepine use in general practice in The Netherlands. Four repeated measurements of benzodiazepine craving were taken over a 21-month follow-up period. Results indicated that (1) benzodiazepine craving severity decreased over time, (2) patients still using benzodiazepines experienced significantly more severe craving than patients who had quit their use after one of the two interventions, and (3) the way in which patients had attempted to quit did not influence the experienced craving severity over time, however, (4) patients who had received additional tapering off, on average, reported significantly more severe craving than patients who had only received a letter as an incentive to quit. Although benzodiazepine craving is prevalent among (former) long-term benzodiazepine users during and after discontinuation, craving severity decreases over time to negligible proportions. Self-reported craving can be longitudinally monitored and quantified by means of the BCQ.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Anti-Anxiety Agents / adverse effects*
  • Behavior Therapy*
  • Behavior, Addictive / psychology
  • Benzodiazepines / adverse effects*
  • Correspondence as Topic
  • Epidemiologic Methods
  • Family Practice
  • Female
  • Humans
  • Male
  • Middle Aged
  • Psychometrics
  • Self Efficacy
  • Socioeconomic Factors
  • Substance Withdrawal Syndrome / diagnosis*
  • Substance Withdrawal Syndrome / etiology
  • Substance Withdrawal Syndrome / therapy
  • Substance-Related Disorders / therapy

Substances

  • Anti-Anxiety Agents
  • Benzodiazepines